Oct 11, 2018
As the name suggests, "evidence-based medicine" is dependent on
published evidence to support our clinical practice and medical
decision making. Implicit in this is the notion that all published
evidence reflects the truth that underlies the biology,
pathophysiology, and pharmacology of our health.
This is not the case.
Clinical research and published findings can be extremely
limited, and what you read in Lancet and NEJM
should be interpreted with caution. In this week's episode of the
"I wonder" series, where Jim Siegler speaks with Ali Hamedani on
various topics in medicine and neurology, the speakers review the
major biases inherent to the practice and interpretation of
Produced by James E. Siegler. Music by Jahzzar, Kai Engel, and
Lee Rosevere. Sound effects by Mike Koenig, Daniel Simion.
BrainWaves' podcasts and online content are intended for medical
education only and should not be used for clinical decision
- Randomised trial of intravenous streptokinase, oral aspirin,
both, or neither among 17,187 cases of suspected acute myocardial
infarction: ISIS-2. ISIS-2 (Second International Study of Infarct
Survival) Collaborative Group. Lancet. 1988;2:349-60.
- Smith GC and Pell JP. Parachute use to prevent death and major
trauma related to gravitational challenge: systematic review of
randomised controlled trials. Bmj. 2003;327:1459-61.
- Kazui H, Miyajima M, Mori E, Ishikawa M and Investigators S-.
Lumboperitoneal shunt surgery for idiopathic normal pressure
hydrocephalus (SINPHONI-2): an open-label randomised trial. The
Lancet Neurology. 2015;14:585-94.
- Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G,
de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan
KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P,
Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS and
Investigators OC. Ocrelizumab versus Placebo in Primary Progressive
Multiple Sclerosis. The New England journal of medicine.